JP7007379B2 - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
JP7007379B2
JP7007379B2 JP2019527071A JP2019527071A JP7007379B2 JP 7007379 B2 JP7007379 B2 JP 7007379B2 JP 2019527071 A JP2019527071 A JP 2019527071A JP 2019527071 A JP2019527071 A JP 2019527071A JP 7007379 B2 JP7007379 B2 JP 7007379B2
Authority
JP
Japan
Prior art keywords
component
pharmaceutical composition
mass
pemafibrate
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019527071A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019004448A1 (ja
Inventor
明人 南園
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of JPWO2019004448A1 publication Critical patent/JPWO2019004448A1/ja
Priority to JP2022000971A priority Critical patent/JP2022033328A/ja
Application granted granted Critical
Publication of JP7007379B2 publication Critical patent/JP7007379B2/ja
Priority to JP2023197141A priority patent/JP2024014994A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019527071A 2017-06-30 2018-06-29 医薬組成物 Active JP7007379B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022000971A JP2022033328A (ja) 2017-06-30 2022-01-06 医薬組成物（２）
JP2023197141A JP2024014994A (ja) 2017-06-30 2023-11-21 医薬組成物（３）

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017128683 2017-06-30
JP2017128683 2017-06-30
PCT/JP2018/024883 WO2019004448A1 (ja) 2017-06-30 2018-06-29 医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022000971A Division JP2022033328A (ja) 2017-06-30 2022-01-06 医薬組成物（２）

Publications (2)

Publication Number Publication Date
JPWO2019004448A1 JPWO2019004448A1 (ja) 2020-04-30
JP7007379B2 true JP7007379B2 (ja) 2022-02-10

Family

ID=64741597

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019527071A Active JP7007379B2 (ja) 2017-06-30 2018-06-29 医薬組成物
JP2018126046A Pending JP2019011323A (ja) 2017-06-30 2018-07-02 医薬組成物
JP2022000971A Pending JP2022033328A (ja) 2017-06-30 2022-01-06 医薬組成物（２）
JP2023197141A Pending JP2024014994A (ja) 2017-06-30 2023-11-21 医薬組成物（３）

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018126046A Pending JP2019011323A (ja) 2017-06-30 2018-07-02 医薬組成物
JP2022000971A Pending JP2022033328A (ja) 2017-06-30 2022-01-06 医薬組成物（２）
JP2023197141A Pending JP2024014994A (ja) 2017-06-30 2023-11-21 医薬組成物（３）

Country Status (3)

Country Link
US (2) US20200121648A1 (enExample)
JP (4) JP7007379B2 (enExample)
WO (1) WO2019004448A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019011323A (ja) * 2017-06-30 2019-01-24 興和株式会社 医薬組成物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI829840B (zh) * 2018-12-27 2024-01-21 日商興和股份有限公司 醫藥組成物
JP7058763B2 (ja) * 2018-12-27 2022-04-22 興和株式会社 医薬品
US20220054458A1 (en) * 2018-12-27 2022-02-24 Kowa Company, Ltd. Pharmaceutical preparation
JP2022013875A (ja) * 2020-06-30 2022-01-18 興和株式会社 医薬組成物
JP2022023005A (ja) * 2020-06-30 2022-02-07 興和株式会社 医薬品

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023777A1 (ja) 2003-09-03 2005-03-17 Kowa Co., Ltd. Ppar活性化化合物及びこれを含有する医薬組成物
WO2014050134A1 (ja) 2012-09-27 2014-04-03 興和株式会社 脂質異常症治療剤
WO2015005365A1 (ja) 2013-07-10 2015-01-15 興和株式会社 非アルコール性脂肪性肝疾患治療剤
WO2015141662A1 (ja) 2014-03-18 2015-09-24 武田薬品工業株式会社 固体分散体
JP2015218322A (ja) 2014-05-21 2015-12-07 旭化成ケミカルズ株式会社 微小澱粉粒子及びその製造方法
JP2016535055A (ja) 2013-11-08 2016-11-10 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
WO2007083679A1 (ja) * 2006-01-20 2007-07-26 Dainippon Sumitomo Pharma Co., Ltd. 新規なフィルムコーティング錠
KR20180014778A (ko) * 2015-06-03 2018-02-09 트리아스텍 인코포레이티드 제형 및 이의 용도
JP7007379B2 (ja) * 2017-06-30 2022-02-10 興和株式会社 医薬組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023777A1 (ja) 2003-09-03 2005-03-17 Kowa Co., Ltd. Ppar活性化化合物及びこれを含有する医薬組成物
WO2014050134A1 (ja) 2012-09-27 2014-04-03 興和株式会社 脂質異常症治療剤
WO2015005365A1 (ja) 2013-07-10 2015-01-15 興和株式会社 非アルコール性脂肪性肝疾患治療剤
JP2016535055A (ja) 2013-11-08 2016-11-10 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 製剤
WO2015141662A1 (ja) 2014-03-18 2015-09-24 武田薬品工業株式会社 固体分散体
JP2015218322A (ja) 2014-05-21 2015-12-07 旭化成ケミカルズ株式会社 微小澱粉粒子及びその製造方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019011323A (ja) * 2017-06-30 2019-01-24 興和株式会社 医薬組成物

Also Published As

Publication number Publication date
WO2019004448A1 (ja) 2019-01-03
US20200121648A1 (en) 2020-04-23
JP2024014994A (ja) 2024-02-01
JPWO2019004448A1 (ja) 2020-04-30
JP2022033328A (ja) 2022-02-28
US20230414578A1 (en) 2023-12-28
JP2019011323A (ja) 2019-01-24

Similar Documents

Publication Publication Date Title
JP7007379B2 (ja) 医薬組成物
CA2861480C (en) Oral composition comprising .alpha.,.alpha.,.alpha.-trifluorothymidine (ftd), 5-chloro-6-(2-iminopyrrolidine-1-yl)methyl-2,4(1h,3h)-pyrimidine dione hydrochloride (tpi)
JP2022082820A (ja) 医薬組成物
JP2022088683A (ja) 医薬組成物
JP2022082821A (ja) 医薬組成物
JP2022082819A (ja) 医薬組成物
JP2015061828A (ja) 口腔内崩壊錠及びその製造方法
JP2019011328A (ja) 医薬品
JP2019011327A (ja) 医薬組成物
WO2012057103A1 (ja) 医薬組成物
JP7071538B2 (ja) 医薬組成物
JP2025105966A (ja) 医薬組成物
JP2022013875A (ja) 医薬組成物
JP2023095805A (ja) 医薬組成物、並びにピレンゼピン塩酸塩水和物及びアズレンスルホン酸ナトリウム水和物の安定化方法
HK40017137A (en) Pharmaceutical composition

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220106

R150 Certificate of patent or registration of utility model

Ref document number: 7007379

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250